Mean change in IOP from pre‐LTP within 2 hours · people with glaucoma receiving LTP
1 finding from 1 review
IOP increase of ≥ 5 mmHg between 2 and 24 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
IOP increase of ≥ 10 mmHg between 2 and 24 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in IOP from pre‐LTP between 2 and 24 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
IOP increase of ≥ 5 mmHg within 2 hours · people with glaucoma receiving LTP
It is very uncertain whether brimonidine changes IOP increase of ≥ 5 mmHg within 2 hours compared with apraclonidine (very low certainty).
1 finding from 1 review
IOP increase of ≥ 10 mmHg within 2 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity Patient Satisfaction Assessment ‐ grade 2 improvement · Participants with rosacea
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
1 finding from 1 review
Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Lesion count ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with rosacea
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review